Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
40
pubmed:dateCreated
2005-10-7
pubmed:abstractText
Hutchinson-Gilford progeria syndrome (HGPS) is a devastating premature aging disease resulting from a mutation in the LMNA gene, which encodes nuclear lamins A and C. Lamin A is synthesized as a precursor (prelamin A) with a C-terminal CaaX motif that undergoes farnesylation, endoproteolytic cleavage, and carboxylmethylation. Prelamin A is subsequently internally cleaved by the zinc metalloprotease Ste24 (Zmpste24) protease, which removes the 15 C-terminal amino acids, including the CaaX modifications, to yield mature lamin A. HGPS results from a dominant mutant form of prelamin A (progerin) that has an internal deletion of 50 aa near the C terminus that includes the Zmpste24 cleavage site and blocks removal of the CaaX-modified C terminus. Fibroblasts from HGPS patients have aberrant nuclei with irregular shapes, which we hypothesize result from the abnormal persistence of the farnesyl and/or carboxylmethyl CaaX modifications on progerin. If this hypothesis is correct, inhibition of CaaX modification by mutation or pharmacological treatment should alleviate the nuclear morphology defect. Consistent with our hypothesis, we find that expression in HeLa cells of GFP-progerin or an uncleavable form of prelamin A with a Zmpste24 cleavage site mutation induces the formation of abnormal nuclei similar to those in HGPS fibroblasts. Strikingly, inhibition of farnesylation pharmacologically with the farnesyl transferase inhibitor rac-R115777 or mutationally by alteration of the CaaX motif dramatically reverses the abnormal nuclear morphology. These results suggest that farnesyl transferase inhibitors represent a possible therapeutic option for individuals with HGPS and/or other laminopathies due to Zmpste24 processing defects.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-10514485, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-11020273, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-11581258, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-11923874, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-12118250, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-12154369, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-12235369, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-12702809, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-12714972, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-12913070, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-14508086, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-14755334, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-15145358, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-15184648, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-15268757, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-15381760, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-15479156, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-15479179, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-15517000, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-1557405, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-15608054, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-15750600, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-15773744, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-15843403, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-2335559, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-2557160, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-8056827, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-8157662, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-8811180, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-9015299, http://linkedlifedata.com/resource/pubmed/commentcorrection/16186497-9700155
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0027-8424
pubmed:author
pubmed:issnType
Print
pubmed:day
4
pubmed:volume
102
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
14416-21
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
pubmed:affiliation
Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural